Q3 2025 Earnings Estimate for TransMedics Group, Inc. Issued By William Blair (NASDAQ:TMDX)

TransMedics Group, Inc. (NASDAQ:TMDX) – Equities researchers at William Blair lifted their Q3 2025 earnings per share (EPS) estimates for shares of TransMedics Group in a research note issued on Tuesday, April 30th. William Blair analyst R. Daniels now anticipates that the company will post earnings per share of $0.12 for the quarter, up from their previous forecast of $0.09. The consensus estimate for TransMedics Group’s current full-year earnings is ($0.14) per share. William Blair also issued estimates for TransMedics Group’s FY2025 earnings at $0.27 EPS.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Tuesday, April 30th. The company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.40. TransMedics Group had a positive return on equity of 8.29% and a negative net margin of 3.43%. The company had revenue of $96.90 million during the quarter, compared to the consensus estimate of $83.78 million. During the same quarter last year, the company earned ($0.08) earnings per share. TransMedics Group’s quarterly revenue was up 132.9% compared to the same quarter last year.

A number of other research analysts have also recently issued reports on the stock. TD Cowen increased their target price on shares of TransMedics Group from $100.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday. JPMorgan Chase & Co. raised their price objective on TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a research note on Wednesday. Canaccord Genuity Group boosted their target price on TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a research report on Wednesday. Piper Sandler restated an “overweight” rating and issued a $120.00 price target (up previously from $95.00) on shares of TransMedics Group in a research report on Wednesday. Finally, Oppenheimer boosted their price objective on shares of TransMedics Group from $105.00 to $125.00 and gave the stock an “outperform” rating in a research report on Wednesday. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $119.00.

TransMedics Group Stock Up 2.9 %

Shares of NASDAQ TMDX opened at $127.99 on Thursday. The stock has a market capitalization of $4.19 billion, a price-to-earnings ratio of -376.44 and a beta of 1.87. TransMedics Group has a 52 week low of $36.42 and a 52 week high of $129.66. The firm has a 50-day moving average price of $85.54 and a 200 day moving average price of $76.85. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69.

Insider Transactions at TransMedics Group

In related news, Director James R. Tobin sold 15,040 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $106.43, for a total transaction of $1,600,707.20. Following the sale, the director now owns 205,171 shares of the company’s stock, valued at $21,836,349.53. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, Director James R. Tobin sold 15,040 shares of the business’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $106.43, for a total value of $1,600,707.20. Following the completion of the transaction, the director now owns 205,171 shares of the company’s stock, valued at approximately $21,836,349.53. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Tamer I. Khayal sold 63,260 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $108.54, for a total transaction of $6,866,240.40. Following the completion of the transaction, the insider now owns 9,792 shares in the company, valued at $1,062,823.68. The disclosure for this sale can be found here. Insiders sold a total of 236,378 shares of company stock valued at $23,633,449 over the last three months. 7.00% of the stock is currently owned by insiders.

Institutional Trading of TransMedics Group

Hedge funds have recently bought and sold shares of the company. Venturi Wealth Management LLC purchased a new position in shares of TransMedics Group during the 1st quarter worth $30,000. Fidelis Capital Partners LLC purchased a new position in TransMedics Group during the first quarter worth about $35,000. Cutler Group LLC CA lifted its position in TransMedics Group by 600.0% during the third quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock worth $38,000 after buying an additional 600 shares during the period. RiverPark Advisors LLC acquired a new stake in TransMedics Group in the 3rd quarter worth about $60,000. Finally, First Horizon Advisors Inc. grew its holdings in TransMedics Group by 26.8% in the 4th quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock valued at $83,000 after buying an additional 222 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.